文献速递流行病学与生物统计临床试验与 GCP

老年人视力损害筛查:美国预防服务工作组更新版证据报告与系统综述

Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

本更新系统综述纳入25项研究(N=33 586),评估老年人视力损害筛查及湿性/干性年龄相关性黄斑变性治疗。4项试验(n=4819)发现筛查与不筛查在视力或其他结局上无显著差异;视力表检查和筛查问题诊断准确性欠佳。湿性AMD中VEGF抑制剂与假治疗相比可提高视力增益≥15个字母的可能性(RR 2.92,95%CI 1.20-7.12;I²=76%;ARD 10%)。

要点

  • 4项试验(n=4819)发现筛查与不筛查在视力或其他结局上无显著差异。
  • 湿性AMD中VEGF抑制剂较假治疗提高视力增益≥15个字母的可能性(RR 2.92,95%CI 1.20-7.12;I²=76%)。
  • 干性AMD中抗氧化复方维生素较安慰剂降低进展至晚期AMD风险(OR 0.72,95%CI 0.58-0.90)。

核心结论

  • 本综述发现老年人视力损害的常见病因存在有效治疗,但直接证据未发现基层筛查与不筛查在改善视力结局方面存在显著关联。

研究设计与样本

  • 针对美国预防服务工作组(USPSTF)的更新版证据报告与系统综述,检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统综述数据库(至2021年2月),监测至2022年1月21日。
  • 纳入随机临床试验和对照观察性研究,涉及筛查、血管内皮生长因子(VEGF)抑制剂(湿性AMD)、抗氧化维生素和矿物质(干性AMD)以及筛查诊断准确性研究。
  • 共纳入25项研究(N=33 586),包括13项试验、11项诊断准确性研究和1项系统综述(含19项试验)。

主要发现

  • 4项试验(n=4819)发现筛查与不筛查在视力或其他结局上无显著差异。
  • 视力表检查(3项研究;n=6493)和筛查问题(3项研究;n=5203)的诊断准确性欠佳。
  • 湿性AMD中,4项试验(n=2086)发现VEGF抑制剂与假治疗相比显著提高视力增益≥15个字母的可能性(RR 2.92,95%CI 1.20-7.12;I²=76%;绝对风险差10%)并显著降低视力丧失≥15个字母的可能性(RR 1.46,95%CI 1.22-1.75;I²=80%;绝对风险差27%),且未增加严重危害风险。
  • 干性AMD中,一项系统综述(19项试验)发现抗氧化复方维生素与安慰剂相比显著降低进展至晚期AMD的风险(3项试验,n=2445;OR 0.72,95%CI 0.58-0.90)和视力丧失≥3行的风险(1项试验,n=1791;OR 0.77,95%CI 0.62-0.96)。
  • 锌与泌尿生殖事件风险增加显著相关,β-胡萝卜素与既往吸烟者肺癌风险增加显著相关;其他严重危害不常见。

关键数值与推荐

  • 湿性AMD:VEGF抑制剂 vs 假治疗,视力增益≥15个字母的RR 2.92(95%CI 1.20-7.12;I²=76%;ARD 10%);视力丧失≥15个字母的RR 1.46(95%CI 1.22-1.75;I²=80%;ARD 27%)。
  • 干性AMD:抗氧化复方维生素 vs 安慰剂,进展至晚期AMD的OR 0.72(95%CI 0.58-0.90;3项试验,n=2445);视力丧失≥3行的OR 0.77(95%CI 0.62-0.96;1项试验,n=1791)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A 2016 review for the US Preventive Services Task Force (USPSTF) found that effective treatments are available for refractive errors, cataracts, and wet (advanced neovascular) or dry (atrophic) age-related macular degeneration (AMD), but there were no differences between visual screening vs no screening on visual acuity or other outcomes. OBJECTIVE: To update the 2016 review on screening for impaired visual acuity in older adults, to inform the USPSTF. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (to February 2021); surveillance through January 21, 2022. STUDY SELECTION: Randomized clinical trials and controlled observational studies on screening, vascular endothelial growth factor (VEGF) inhibitors (wet AMD), and antioxidant vitamins and minerals (dry AMD); studies on screening diagnostic accuracy. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data and a second checked accuracy. Two investigators independently assessed study quality. RESULTS: Twenty-five studies (N = 33 586) were included (13 trials, 11 diagnostic accuracy studies, and 1 systematic review [19 trials]). Four trials (n = 4819) found no significant differences between screening vs no screening in visual acuity or other outcomes. Visual acuity tests (3 studies; n = 6493) and screening question (3 studies; n = 5203) were associated with suboptimal diagnostic accuracy. For wet AMD, 4 trials (n = 2086) found VEGF inhibitors significantly associated with greater likelihood of 15 or more letters visual acuity gain (risk ratio [RR], 2.92 [95% CI, 1.20-7.12]; I2 = 76%; absolute risk difference [ARD], 10%) and less than 15 letters visual acuity loss (RR, 1.46 [95% CI, 1.22-1.75]; I2 = 80%; ARD, 27%) vs sham treatment, with no increased risk of serious harms. For dry AMD, a systematic review (19 trials) found antioxidant multivitamins significantly associated with decreased risk of progression to late AMD (3 trials, n = 2445; odds ratio [OR], 0.72 [95% CI, 0.58-0.90]) and 3 lines or more visual acuity loss (1 trial, n = 1791; OR, 0.77 [95% CI, 0.62-0.96]) vs placebo. Zinc was significantly associated with increased risk of genitourinary events and beta carotene with increased risk of lung cancer in former smokers; other serious harms were infrequent. CONCLUSIONS AND RELEVANCE: This review found that effective treatments are available for common causes of impaired visual acuity in older adults. However, direct evidence found no significant association between vision screening vs no screening in primary care and improved visual outcomes.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chou R, Bougatsos C, Jungbauer R, et al. Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35608842. doi:10.1001/jama.2022.6381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。